Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus EGFR TKI in EGFR-mutated NSCLC
NCT06071013Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Feb 2024
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by China Medical University Hospital. Primary endpoints: Toxicity of combined nintedanib and EGFR TKI and Objective Response Rate. Started Feb 2024; status: recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06071013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071013.